Share Name Share Symbol Market Type Share ISIN Share Description
Touchstone Innovations LSE:IVO London Ordinary Share GB00B170L953 ORD 3 1/33P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 305.50p 303.75p 315.00p - - - 1,408 14:24:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 4.3 -63.1 -43.2 - 492.48

Touchstone Innovations Share Discussion Threads

Showing 51 to 70 of 75 messages
Chat Pages: 3  2  1
Ivo NAV now higher than current offer and further events might straddle year end but not massive impact. Something has to move or offer could fail. Snapping up ivo below NAV would be a coup but what chance? Big holders won't suffer (they hold both) but ipo smaller holders will be diluted further in enlarged group with higher % going to ivo. Just mht.
Big shareholders banging ivo/ipo bod heads together might help.
AB: SP movement is currently more outside IVO's control than ever. The same big investors in both IP Group and IVO seem largely supportive of a takeover by IP Group of IVO at 2.1575 shares in IPO for each IVO - which pretty well sets today's price (IPO currently at about 128.) Management of IVO are not supportive advising shareholders to take no action at this time citing undervaluation as one reason of concern - but their power/sway seems limited by the big investors. The way (perhaps) to protect yourself from this arguably low ball offer is to consider buying IP shares. Personally, I think IVO shareholders without compensating holdings in IPO are being taken for a journey.
This is not a short term holding, and the way things have been going, not a long term one either! If one's interested in start-ups, new businesses, technology or otherwise, I'm thinking a VCT, or an EIS portfolio would be better. At least you get tax relief on buying in, and other tax benefits whilst holding and disposing (eventually). Touchstone doesn't seem to be touching any stones of value right now. It appears more of a bet where your stake may or may not come back in full at some future date, whilst you wait for a win. I'm holding, and not folding immediately because I'm giving it more time, but my patience is not boundless.
Good companies are usually proud of their people and processes so that's understandable but the statement is weak given 3 large shareholders support IPO'S move. It reads that it comes down to money and ego no matter what they say about the portfolio. A) What merits? He doesn't state them clearly. Alluding to them and not stating what they are is not cricket. Nil points for that. "........and because the proposal had certain merits, the Board agreed to engage." What merits? Being clear helps. B) They want more money and keep positions at same level or higher in terms of job description and/or corporate level and same processes. "Meetings were held, but no real progress was made on two very important issues: first, on the valuation of Touchstone, and second, on the need to retain and build on the best of both companies and to establish a clear understanding of joint strategy, corporate governance and management." I hold IPO and IVO and will vote FOR. IPO, IVO, WPCT are all on the receiving end of less than positive market sentiment hence the valuation. IPO are being opportunistic but that's always a risk when the market has a downer on a market segment.
Take over rejected - Question - Will IP group go hostile and would major shareholder support them?
Buyout in the offing and Pbb still dead. A good sign.
Today : Monday 10 October 2016 Click Here for more Imperial Innov Charts. TIDMIVO RNS Number : 1365M Imperial Innovations Group plc 10 October 2016 10 October 2016 Imperial Innovations Group plc Portfolio company Crescendo Biologics signs collaboration and licence agreement with Takeda worth up to $790m IVO owns around 22% of Crescendo.. saffy..
Covered in The Times' Tempus column today, on the back of yesterday's investment in UCL Fund. Final paragraph: "The shares, up 10p at 370p, have taken a bit of a battering of late, for no obvious reason. I have highlighted Imperial before as an attractive long-term investment and I would do so again, although you may need to be patient."
7% Spread on a 600 million pounder of a stock. Total volume 5000 shares per day! that is only £23,000 This is now in the uninvestible bin. On that it should be sitting at a discount to its NAV of about 20%
Full interview: 14 October 2015: Russ Cummings, CEO of Imperial Innovations tells IG that it continues to benefit from its investment to build businesses. Immediately after Imperial published full-year results Stifel issued a buy target of 601p.
Very downbeat article in the Sunday Times, behind its paywall at hTTp:// In essence, saying they haven't pulled off any mega-investments (with trebling their investment in Circassia the only biggish win) and as a result share price growth has been barely 3% p.a. over many years. It's certainly been very quiet for an extended period, hopefully there are a few future unicorns tucked away in the portfolio - full year results out on Wednesday so maybe some useful updates to come.
Interview with CEO Russ Cummings Russ Cummings, the chief executive of Imperial Innovations (LON:IVO), says the university commercialisation business is in a strong position after its recent fundraising. He says the £150mln placing will last the company ‘a good, long period’ and adds that so-called tax inversion deals ‘don’t really affect us’. The group’s annual results today showed a 38% rise in the value of its portfolio to £252mln.
Not in yet but he is known for is long and safe bets
Found this in the telegraph may be of interest, Imperial Innovations is by far the smallest company in the Woodford Equity Income top 10, with a market value of about £390m. AstraZeneca, by comparison, has a market value of almost £56bn. Imperial Innovations accounts for 3.6pc of the Woodford fund, which means that the fund owns about 13.5pc of the company. It is understood that Mr Woodford took advantage of an opportunity to buy Imperial Innovations shares and won't seek to maintain its current weighting as the fund grows. Taking a large stake in a relatively small company is not always possible without causing the price to rise sharply
I noticed that too. The only thing I have found is this; 'I must confess I have always had a soft spot for Imperial Innovations, the company that invests in technologies developed at some of the UK's top universities. Its origins lie just around the corner from the Evening Standard's Kensington office, in Exhibition Road where Imperial College resides. Imperial Innovations was set up as the technology transfer office for the college in 1986. It floated 20 years later, raising £25 million through a share offer at 365p that valued it at £180 million. There have been a couple more fund-raisers totalling just over £180 million since then. The market cap has inched its way up to just over £410 million. The shares have gone from 365p to 412p in eight years. That's hardly shooting the lights out - but look at the price over just the last seven months, and it has come up an impressive 58%. What's going on? Two things: in 2011, Imperial extended its technological tie-ups to take in research at University College London, Oxford and Cambridge. Talk to chief executive Russell Cummings, and you find the technology being done by investee companies more often comes from at least two of these centres of learning rather than just one. Second, as recent half-year results showed, Innovations is a maturing company. From a handful of investments when it floated, it now has holdings in well over 30 companies. These generally take between eight and 12 years to come to fruition, normally through a flotation. The recent big one was cat-allergy treatment developer Circassia, which floated last month with a value of £581 million. Imperial still owns 19% of the business, and saw the value of that stake rise from £45 million in July 2013 to £73 million in December, and £82 million at float. The big gains in Imperial's portfolio come just before its offspring head for the stock market. Now while Cummings was being cagey about naming names, he made it clear the pipeline of floats is looking good. Word is that companies like Cell Medica (cellular therapeutics), PsiOxus (biotech), Veryan Medical (vascular disease) and PolyTherics (biopharma) are well on their way to listings. Not only are Imperial companies maturing, but so too is the breadth and depth of its management. At the same time, its investor base (dominated by Imperial College itself and Invesco Perpetual) is a bunch of long-term holders. After a roller-coaster first eight years, it looks the right time to get on board for the next eight.'
Another big jump today without any apparent news.
For those interested I rently contacted H&L re the proposed IPO of Circassia Holdings,and they confirmed they will be accepting orders for the issue subject to acceptance by the issuer, which will be considered firm once placed. Also orders will be subject to a commission at a flat rate of £100. One won't be able to place them via your ISA though.
11:53 IVO are a research client of Edison. share price is currently at a 73% premium to NAV BUT Circassia IPO may change all this. Fund continues to have access to cash.
The Circassia float marks the start of a new era of major exits and will transform the profile of IVO. I have bought some for my SIPP and await developments and dividends?
Chat Pages: 3  2  1
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170817 13:53:55